The Emerging Roles of ARID1A in Tumor Suppression

Overview

Journal Cancer Biol Ther

Specialties Oncology
Pharmacology

Date 2014 Mar 13

PMID 24618703

Citations 136

Authors

Ren-Chin Wu

Tian-Li Wang

Ie-Ming Shih

Affiliations

Soon will be listed here.

Abstract

ARID1A has emerged as a tumor suppressor gene, which is mutated in a broad spectrum of cancers, especially in those arising from ectopic or eutopic endometrium. As a subunit of SWI/SNF chromatin remodeler, ARID1A facilitates target-specific binding of SWI/SNF complexes to chromatin, thereby altering the accessibility of chromatin to a variety of nuclear factors. In human cancer, ARID1A possesses not only features of a gatekeeper, regulating cell cycle progression, but also features of a caretaker, preventing genomic instability. An increasing body of evidence suggests crosstalk between ARID1A and PI3K/Akt pathways, and between ARID1A and p53. In this review, we discuss the spectrum of ARID1A alterations in cancers, tumor suppression mechanisms of ARID1A, oncogenic pathways cooperating with ARID1A, and clinical implications of ARID1A mutation.

Citing Articles

Comprehensive clinical and genetic characterization of hyperprogressive biliary tract cancer during PD-1 blockade monotherapy: case report and literature review.

Wang K, Yang X, Guo F, Sun H, Fang Y, Jiang N BMC Med Genomics. 2025; 18(1):52.

PMID: 40087618 DOI: 10.1186/s12920-025-02097-5.

Targeting USP8 causes synthetic lethality through degradation of FGFR2 in ARID1A-deficient ovarian clear cell carcinoma.

Saito R, Fukushima M, Sasaki M, Okamoto A, Ogiwara H NPJ Precis Oncol. 2025; 9(1):69.

PMID: 40074856 PMC: 11903656. DOI: 10.1038/s41698-025-00850-8.

Loss of ARID1A accelerates prostate tumourigenesis with a proliferative collagen-poor phenotype through co-operation with AP1 subunit cFos.

Hartley A, Galbraith L, Shaw R, Tibbo A, Veeratterapillay R, Wilson L Br J Cancer. 2025; .

PMID: 39885328 DOI: 10.1038/s41416-025-02944-3.

Advances in the study of the role of high-frequency mutant subunits of the SWI/SNF complex in tumors.

Zhao J, Zhu J, Tang Y, Zheng K, Li Z Front Oncol. 2024; 14:1463892.

PMID: 39697230 PMC: 11652375. DOI: 10.3389/fonc.2024.1463892.

AURKA inhibition shows promise as a therapeutic strategy for ARID1A-mutant colorectal cancer.

Qin R, Li C, Chen F, Luo S, Wang C, Li J Discov Oncol. 2024; 15(1):556.

PMID: 39402330 PMC: 11473479. DOI: 10.1007/s12672-024-01433-y.

References

Rahman M, Nakayama K, Rahman M, Katagiri H, Katagiri A, Ishibashi T . Clinicopathologic analysis of loss of AT-rich interactive domain 1A expression in endometrial cancer. Hum Pathol. 2012; 44(1):103-9. DOI: 10.1016/j.humpath.2012.04.021. View

Cajuso T, Hanninen U, Kondelin J, Gylfe A, Tanskanen T, Katainen R . Exome sequencing reveals frequent inactivating mutations in ARID1A, ARID1B, ARID2 and ARID4A in microsatellite unstable colorectal cancer. Int J Cancer. 2014; 135(3):611-23. DOI: 10.1002/ijc.28705. View

. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012; 489(7417):519-25. PMC: 3466113. DOI: 10.1038/nature11404. View

Fadare O, Gwin K, Desouki M, Crispens M, Jones 3rd H, Khabele D . The clinicopathologic significance of p53 and BAF-250a (ARID1A) expression in clear cell carcinoma of the endometrium. Mod Pathol. 2013; 26(8):1101-10. PMC: 3886836. DOI: 10.1038/modpathol.2013.35. View

Zhang X, Zhang Y, Yang Y, Niu M, Sun S, Ji H . Frequent low expression of chromatin remodeling gene ARID1A in breast cancer and its clinical significance. Cancer Epidemiol. 2011; 36(3):288-93. DOI: 10.1016/j.canep.2011.07.006. View

Chan-On W, Nairismagi M, Ong C, Lim W, Dima S, Pairojkul C . Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet. 2013; 45(12):1474-8. DOI: 10.1038/ng.2806. View

Luo B, Cheung H, Subramanian A, Sharifnia T, Okamoto M, Yang X . Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A. 2008; 105(51):20380-5. PMC: 2629277. DOI: 10.1073/pnas.0810485105. View

Wiegand K, Shah S, Al-Agha O, Zhao Y, Tse K, Zeng T . ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 2010; 363(16):1532-43. PMC: 2976679. DOI: 10.1056/NEJMoa1008433. View

Guan B, Wang T, Shih I . ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res. 2011; 71(21):6718-27. PMC: 3206175. DOI: 10.1158/0008-5472.CAN-11-1562. View

10.

Dulak A, Stojanov P, Peng S, Lawrence M, Fox C, Stewart C . Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet. 2013; 45(5):478-86. PMC: 3678719. DOI: 10.1038/ng.2591. View

11.

Igney F, Krammer P . Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leukoc Biol. 2002; 71(6):907-20. View

12.

Dawson M, Kouzarides T . Cancer epigenetics: from mechanism to therapy. Cell. 2012; 150(1):12-27. DOI: 10.1016/j.cell.2012.06.013. View

13.

Nagl Jr N, Patsialou A, Haines D, Dallas P, Beck Jr G, Moran E . The p270 (ARID1A/SMARCF1) subunit of mammalian SWI/SNF-related complexes is essential for normal cell cycle arrest. Cancer Res. 2005; 65(20):9236-44. DOI: 10.1158/0008-5472.CAN-05-1225. View

14.

Yamamoto S, Tsuda H, Takano M, Tamai S, Matsubara O . Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations. Mod Pathol. 2011; 25(4):615-24. DOI: 10.1038/modpathol.2011.189. View

15.

Krig S, Miller J, Frietze S, Beckett L, Neve R, Farnham P . ZNF217, a candidate breast cancer oncogene amplified at 20q13, regulates expression of the ErbB3 receptor tyrosine kinase in breast cancer cells. Oncogene. 2010; 29(40):5500-10. PMC: 4256946. DOI: 10.1038/onc.2010.289. View

16.

Chandler R, Brennan J, Schisler J, Serber D, Patterson C, Magnuson T . ARID1a-DNA interactions are required for promoter occupancy by SWI/SNF. Mol Cell Biol. 2012; 33(2):265-80. PMC: 3554127. DOI: 10.1128/MCB.01008-12. View

17.

Heery D, Kalkhoven E, Hoare S, Parker M . A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature. 1997; 387(6634):733-6. DOI: 10.1038/42750. View

18.

Mao T, Ardighieri L, Ayhan A, Kuo K, Wu C, Wang T . Loss of ARID1A expression correlates with stages of tumor progression in uterine endometrioid carcinoma. Am J Surg Pathol. 2013; 37(9):1342-8. PMC: 3787317. DOI: 10.1097/PAS.0b013e3182889dc3. View

19.

Chong I, Cunningham D, Barber L, Campbell J, Chen L, Kozarewa I . The genomic landscape of oesophagogastric junctional adenocarcinoma. J Pathol. 2013; 231(3):301-10. DOI: 10.1002/path.4247. View

20.

Sausen M, Leary R, Jones S, Wu J, Reynolds C, Liu X . Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nat Genet. 2012; 45(1):12-7. PMC: 3557959. DOI: 10.1038/ng.2493. View